Empower Advisory Group LLC Has $50.92 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Empower Advisory Group LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 275,851 shares of the medical research company’s stock after purchasing an additional 6,747 shares during the quarter. Empower Advisory Group LLC owned about 0.54% of Charles River Laboratories International worth $50,922,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in CRL. Versant Capital Management Inc grew its stake in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the period. Pinnacle Bancorp Inc. lifted its holdings in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Assetmark Inc. grew its position in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. ORG Wealth Partners LLC bought a new stake in Charles River Laboratories International during the 4th quarter valued at $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Charles River Laboratories International during the third quarter worth $59,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $152.07 on Tuesday. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $275.00. The business’s fifty day moving average is $175.44 and its 200 day moving average is $189.72. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The firm has a market cap of $7.78 billion, a price-to-earnings ratio of 19.03, a PEG ratio of 6.47 and a beta of 1.37.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on CRL shares. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. UBS Group reissued a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Bank of America cut their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. Finally, William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).